American Healthcare REIT

step: 01 title: Business Model & Overview ticker: AHR company: American Healthcare REIT, Inc. source: coverage-next-full sector_track: REIT created: 2026-06-08

Step 01 — Business Model: American Healthcare REIT (AHR)

1. Business Description

American Healthcare REIT is an internally managed, NYSE-listed real estate investment trust that owns and operates a diversified portfolio of healthcare properties across the United States [S1]. The company's portfolio is organized into three operating segments — Integrated Senior Health Campuses (ISHC), Senior Housing Operating Properties (SHOP), and Outpatient Medical (OM) — representing a continuum from heavy-care skilled nursing to lighter-touch independent living and clinical outpatient care [S1].

The company's predecessor entities (Griffin-American Healthcare REIT III and IV) operated as non-traded REITs from 2013 onwards, merging in 2021 and listing on the NYSE in February 2024 [S1][S2]. Approximately $1.36B in equity was raised at IPO and follow-on (September 2024), enabling the company to pay down ~$1B of high-cost debt and shift its capital structure materially [S2].

The defining strategic characteristic is internal management: unlike most US healthcare REITs, AHR has no external adviser. Management was internalized in 2021 via an approximately $131.7M OP-unit transaction with co-founders and Griffin Capital. This eliminates advisory fees that typically run 0.5–1.5% of assets per year for externally managed peers [S5].

2. Value-Chain Layer Map

Healthcare Need (aging population demand)
          ↓
Property / Real Estate Layer (AHR owns)
   ├── ISHC / Trilogy (owned + operated)
   │     ├── Skilled Nursing Facilities (SNF)
   │     ├── Assisted Living (AL)
   │     ├── Independent Living (IL)
   │     └── Ancillary (pharmacy, therapy, home health)
   ├── SHOP (owned; third-party operators manage)
   │     ├── Assisted Living
   │     ├── Memory Care
   │     └── Independent Living
   └── Outpatient Medical / MOB (owned; NNN + gross leases)
         ├── Medical Office Buildings
         ├── Outpatient Surgery Centers
         └── Specialty Clinic Space
          ↓
Capital Layer (equity + debt financing)
   ├── Common equity (NYSE: AHR ~$8B market cap)
   ├── Revolving credit facility ($600M)
   └── Term loans + mortgage debt (~$1.5B total)
          ↓
Returns to Shareholders (dividends + NFFO growth)

3. Segment Deep Dive

ISHC / Trilogy (Dominant Segment, ~60% of Revenue)

Trilogy Healthcare is a consolidated operating subsidiary — AHR owns 100% following the September 2024 acquisition of NorthStar's remaining 24% minority interest for ~$258M [S2]. Trilogy operates 147 properties concentrated in Indiana, Ohio, Michigan, and Kentucky, providing a full continuum of senior care [S1][S2].

The RIDEA structure means AHR captures both the NOI from real estate and operating income/losses from the healthcare business — higher upside vs. NNN leases, but also direct exposure to staffing costs, labor markets, and Medicare/Medicaid reimbursement [S1]. Trilogy's differentiation: (1) integrated campus model reduces resident transfer (IL→AL→SNF on one campus, avoiding third-party SNF admission), (2) ancillary revenue streams (pharmacy, therapy, home health) add ~$40–60M in incremental annual revenue, (3) strong Midwest referral network from hospital partnerships.

Q4 2025 occupancy: 90.6% — above pre-COVID levels and above industry SNF averages (~78%) [S2].

SHOP (Growth Segment, ~20% of Revenue)

83 properties operated under RIDEA by third-party operators including Discovery Senior Living and Integral Senior Living [S2]. Geographic mix skewed toward Sunbelt states (Florida, Texas, Arizona) and Pacific Coast. Occupancy has been recovering sharply: Q1 2026 same-store NOI growth +19.7% YoY, reflecting combination of occupancy recovery and rate increases [S2].

Unlike ISHC, AHR does not operate SHOP assets directly — it relies on operator execution. Operator selection and monitoring is a key governance risk.

Outpatient Medical / MOB (~20% of Revenue)

71 outpatient medical properties with 22.2M sqft GLA [S1]. These are predominantly long-term NNN or gross leases to health systems (e.g., HCA, Ascension) and independent physician groups. Lease terms typically 7–15 years with annual CPI escalators. Lowest volatility segment; provides cash flow stability. Cap rates for hospital-anchored MOBs run 6.0–6.5% — compressed vs. history but still favorable vs. senior housing pricing [S4].

4. Revenue Model

AHR generates revenue through two primary economic models:

RIDEA (80% of revenue): AHR consolidates the full P&L of ISHC and SHOP properties. Revenue is the gross healthcare facility revenue (room charges, ancillary fees, Medicare/Medicaid). Operating expenses (labor, supplies, overhead) are deducted within the segment. This produces higher absolute revenue and EBITDA but requires management of operational complexity [S1].

NNN/Gross Leases (~20% of revenue): Outpatient Medical properties generate contractual rental income with minimal operating expense at the REIT level. Highly predictable cash flows with CPI-escalated rent bumps [S1].

The strategic shift from NNN senior housing to RIDEA has been central to the AHR story: post-COVID, operators were under-performing under NNN structures, leading AHR to convert leases to RIDEA or acquire operators directly. This increased risk but also captures the full recovery in senior housing economics [S2].

5. Business Cycle Positioning

Healthcare real estate sits in a favorable secular window as of 2026 [S4]:

• 80+ population growing 48% by 2030 (oldest Baby Boomers turn 80 in 2026)
• Senior housing supply growth near all-time lows (~1% inventory growth, units under construction at 2012 lows)
• Occupancy in assisted living/memory care recovering toward 90%+ from COVID trough (~78%)
• Medical office benefiting from outpatient shift in healthcare delivery

AHR is early in its public company lifecycle (listed February 2024), with a NFFO growth path that is partially balance-sheet-driven (deleveraging reducing interest expense) and partially operational (occupancy recovery + same-store NOI compounding). FY2026 NFFO guidance: $2.02–$2.09/share (+17–21% YoY) [S2].

6. Key Business Risks at the Model Level

Source Index

step: 12 title: Bull vs. Bear (Analyst Debate) ticker: AHR company: American Healthcare REIT, Inc. source: coverage-next-full sector_track: REIT created: 2026-06-08

Step 12 — Bull vs. Bear: American Healthcare REIT (AHR)

Note: Earnings transcript analysis was not performed (coverage-next-full path). Bull/bear case inferred from analyst consensus notes, press releases, investor presentations, and recent news. Analyst views sourced from consensus data and public research summaries.

Analyst Consensus Summary

The analyst community is nearly unanimous on AHR (12/13 Buy). The debate is not Buy vs. Sell — it is between those who see the current multiple (~22x FY2026 NFFO) as still cheap vs. those who question execution pace.

The Bull Case

Bull Thesis: "Compounding Healthcare REIT at a Discount to Quality"

AHR is one of the fastest-growing healthcare REITs in the US, with NFFO/share growing 20%+ in each of its first two full public years, operating in the most favorable supply-demand environment for senior housing in a decade. The stock trades at a 35–40% discount to Welltower despite a comparable or superior same-store NOI growth rate. As AHR builds its track record, the multiple should converge toward large-cap peers.

Bull Case — 3 Bullets:

1. Demographic demand + supply constraint = multi-year NOI compounding. The 80+ population grows 48% by 2030; senior housing inventory growth is near historic lows (~1%/year). AHR's SHOP same-store NOI is already at +19.7% YoY (Q1 2026). This tailwind has 5–8 years of runway before supply responds meaningfully. Each year of tight supply adds 3–5% NOI growth on top of the base rate — creating a 10–15% organic growth flywheel for the RIDEA segments.

2. Trilogy is a compounding machine with an underappreciated ancillary revenue layer. Trilogy's integrated campus model generates ancillary services revenue (pharmacy, therapy, home health) that a passive NNN landlord cannot capture. At 90.6% occupancy (above pre-COVID highs) and CMS Medicare reimbursement trending positive, Trilogy's NOI growth has durable fundamental support. The $258M full consolidation in September 2024 was a pivotal capital allocation decision — AHR now captures 100% of a growing earnings stream at below-market cost basis.

3. Balance sheet re-rating is not fully priced in. AHR has compressed Net Debt/EBITDA from 7.5x (pre-IPO) to 3.0x in 2 years while simultaneously growing NFFO. This creates an unusual combination: a growth REIT with one of the lowest leverage ratios in the sector. The $230M+ acquisition pipeline (not in guidance) provides upside surprise potential. Management has beaten NFFO guidance every quarter since IPO. The stock's ~40% discount to Welltower on P/NFFO does not reflect this leverage advantage.

The Bear Case

Bear Thesis: "Crowded Bull Trade with Execution Overhang"

AHR is a recently-public company with a $950M+ acquisition pace, a CEO on medical leave, and a stock that has already moved +275% from IPO price. The near-unanimous Buy rating and premium vs. peers (vs. prior year) leaves limited margin for error. The bull case is widely owned and well-understood; the debate is whether the execution can match the setup.

Bear Case — 3 Bullets:

1. CEO medical leave is a material governance risk that the market is underpricing. Jeff Hanson co-founded and has run this company for 12+ years. His medical leave (February 2026, no return timeline disclosed) creates institutional uncertainty. If the leave becomes permanent, AHR loses its primary architect during a critical growth phase. Danny Prosky appears capable, but a permanent succession event — particularly if combined with any operational miss — could trigger multiple compression and investor reassessment. At 12x buy vs. 1x hold, there is limited incremental demand from consensus upgrades if the story stumbles.

2. Labor cost inflation and CMS minimum staffing rule implementation will compress Trilogy margins in 2026–2028. Healthcare worker wage growth (4–7% annually) and the phased CMS minimum staffing mandate create structural cost headwinds for the ISHC/Trilogy segment. The current same-store NOI growth rate (9–10% at ISHC) partially reflects favorable CMS reimbursement (FY2026 +3.2%) — but if Medicare Advantage penetration accelerates or Medicaid state budgets tighten, the ~73% private-pay mix at Trilogy may prove insufficient to fully offset labor cost pressures. The market currently assumes ~8–10% ISHC same-store NOI growth indefinitely; a reset to 4–6% would compress NFFO growth materially.

3. Acquisition pace creates integration risk and potential re-leveraging. At $950M+ deployed in 2025 and $230M+ in the 2026 pipeline, AHR's asset base is growing fast. The balance sheet improvement (3.0x leverage) could reverse if EBITDA growth disappoints while debt rises. The $600M revolver and floating-rate exposure also create rate sensitivity if the macro environment deteriorates. Smaller healthcare REITs that aggressively acquired in 2014–2018 (including some of AHR's predecessor entities) subsequently faced write-downs and covenant issues when execution fell short. The current cycle could repeat if AHR overpays or absorbs underperforming operators.

Analyst Debate Context

The bull/bear debate at current prices (~$45) is effectively:

Source Index